OncoPharm

Latest Episodes:

Decreased Cardiotoxicity With Infusional Doxorubicin Oct 21, 2021

Show notes

We return to our Landmarks of OncoPharm series to dive deep into an article that provided some of our foundational understanding of how anthracycline cardiotoxicity risk is influenced by rate of administration. Link: https://pubmed.ncbi.nlm.nih.gov/2910423/

Adjuvant Abemaciclib Oct 14, 2021

Show notes

FDA approves 2-years of abemaciclib plus endocrine therapy for high-risk HR+, HER2(-) patients. Quite a bit to discuss about this. Also, FDA expands indications for pembrolizumab (of course) and brexucabtagene autoleucel. NOTE: A 5cm breast tumor is a T3 lesion, not a T2 as misstated in this episode.

Same Day Pegfilgrastim Oct 07, 2021

Show notes

Dr. Ali McBride joins the Pod to spar over same-day vs. next-day pegfilgrastim. (There is some audio feedback early in the Pod that we clean up after a few minutes. Apologies!) Bibliography: Burris et al: https://pubmed.ncbi.nlm.nih.gov/20808556/ AOC: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819939/ McBride et al (CHOP): https://www.futuremedicine.com/doi/10.2217/fon-2021-0532 McBride et al (NHL): https://doi.org/10.18553/jmcp.2021.21010

Sarcomas In A Nutshell Sep 30, 2021

Show notes

An oversimplified approach to thinking about sarcomas.

ESMO21 & New Drugs (Cervical Ca Focus) Sep 23, 2021

Show notes

Lots to discuss from ESMO 2021 to new drug approvals. First, we discuss the updates in cervical cancer from ESMO (pembrolizumab with chemo) and the newly approved tisotumab-vedotin. Then, we discuss another new agent, mobocertinib and its scary QT prolongation profile as well as cabo-confusion in thyroid cancer. Finally, we discuss the potentially practice changing, but preliminary, data from ESMO in bladder cancer (VESPER) and HER2+ MBC (DESTINY-Breast03).

CASSIOPEIA Part 2 Sep 16, 2021

Show notes

Discussing the updated results after the 2nd randomization of CASSIOPEIA looking at daratumumab maintenance following ASCT. Link: https://doi.org/10.1016/S1470-2045(21)00490-3

MMF For ITP Sep 09, 2021

Show notes

Discussing the use of mycophenolate mofetil (MMF) for ITP (https://www.nejm.org/doi/full/10.1056/NEJMoa2100596) as well as regulatory updates on atezolizumab and zanubrutinib.

Hypercalcemia Of Malignancy (in Under 10) Sep 02, 2021

Show notes

Foundations of OncoPharm: Hypercalcemia of Malignancy (in under 10 minutes)

Belzutifan and Recent Updates Aug 26, 2021

Show notes

Belzutifan, the 1st hypoxia-inducible factor (HIF) inhibitor is FDA-approved. Plus, expanded indication approvals for nivolumab, dostarlimab, lenvatinib/pembrolizumab, & Ivosidenib. Finally, my Top 5 Rolling Stones Songs (14:30).

Booster COVID-19 Vaccinations in Immunocompromised Patients Aug 19, 2021

Show notes

Looking into the data behind the FDA & CDC's allowance for a booster mRNA vaccine for immunocompromised patients.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected